Full Text
The Full Text of this article is available as a PDF (36.9 KB).
References
- 1. Conti CR: Partial fatty acid oxidation inhibition: Anew therapy for chronic stable angina. Clin Cardiol 2003; 26: 161–162 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA, for the MARIS A Investigators : Anti‐ischemic effects and long‐term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43 (8): 1375–1382 [DOI] [PubMed] [Google Scholar]
- 3. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators : Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. J Am Med Assoc 2004; 291 (3): 309–316 [DOI] [PubMed] [Google Scholar]
- 4. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, Haddock PS, Karran EH: The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long‐chain 3‐ketoacyl coenzyme Athiolase. Circ Res 2003; 93 (3): e26–e32; Epub 2003 Jul 17 [DOI] [PubMed] [Google Scholar]
- 5. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G: Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110 (8): 904–910; Epub 2004 Aug 9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Undrovinas AI, Undrovinas NA, Belardinelli L, Sabbah HN: Ranolazine inhibits late sodium current in isolated left ventricular myocytes of dogs with heart failure (abstr). J Am Coll Cardiol 2004; 43 (suppl A): 178A;abstr 1068–128 [Google Scholar]
- 7. Belardinelli L, Antzelevitch C, Fraser H: Inhibition of late (sustained/persistent) sodium current: A potential drug target to reduce intracellular sodiumdependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J (supplements) (2004); 6 (supple 1): 13–17 [Google Scholar]
- 8. Belardinelli L, Shryock JC, Fraser H: The mechanism of ranolazine action to reduce ischemia‐induced diastolic dysfunction. Eur Heart J (supplements) 2006; 8 (suppl A): A10–A13 [Google Scholar]